238 related articles for article (PubMed ID: 19183157)
1. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
Sharma P; Shaheen NJ; Perez MC; Pilmer BL; Lee M; Atkinson SN; Peura D
Aliment Pharmacol Ther; 2009 Apr; 29(7):731-41. PubMed ID: 19183157
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
Metz DC; Howden CW; Perez MC; Larsen L; O'Neil J; Atkinson SN
Aliment Pharmacol Ther; 2009 Apr; 29(7):742-54. PubMed ID: 19210298
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
Howden CW; Larsen LM; Perez MC; Palmer R; Atkinson SN
Aliment Pharmacol Ther; 2009 Nov; 30(9):895-907. PubMed ID: 19681809
[TBL] [Abstract][Full Text] [Related]
4. Dexlansoprazole MR: a review.
Hershcovici T; Jha LK; Fass R
Ann Med; 2011 Aug; 43(5):366-74. PubMed ID: 21366513
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
[TBL] [Abstract][Full Text] [Related]
7. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Abel C; Desilets AR; Willett K
Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
[TBL] [Abstract][Full Text] [Related]
8. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
Croxtall JD; Scott LJ
Drugs; 2010 Aug; 70(12):1593-601. PubMed ID: 20687622
[TBL] [Abstract][Full Text] [Related]
9. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor.
Lee RD; Mulford D; Wu J; Atkinson SN
Aliment Pharmacol Ther; 2010 May; 31(9):1001-11. PubMed ID: 20180789
[TBL] [Abstract][Full Text] [Related]
10. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
Zhang W; Wu J; Atkinson SN
J Clin Pharmacol; 2009 Apr; 49(4):444-54. PubMed ID: 19318694
[TBL] [Abstract][Full Text] [Related]
11. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
Metz DC; Vakily M; Dixit T; Mulford D
Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580
[TBL] [Abstract][Full Text] [Related]
12. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Emerson CR; Marzella N
Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
[TBL] [Abstract][Full Text] [Related]
13. The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.
Dabholkar AH; Han C; Paris MM; Perez MC; Atkinson SN; Peura DA
Aliment Pharmacol Ther; 2011 Feb; 33(3):366-77. PubMed ID: 21118280
[TBL] [Abstract][Full Text] [Related]
14. Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.
Vakily M; Wu J; Atkinson SN
J Clin Pharmacol; 2009 Dec; 49(12):1447-55. PubMed ID: 19826060
[TBL] [Abstract][Full Text] [Related]
15. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Apr; 37(8):810-8. PubMed ID: 23451835
[TBL] [Abstract][Full Text] [Related]
16. Dexlansoprazole MR for the management of gastroesophageal reflux disease.
Behm BW; Peura DA
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):439-45. PubMed ID: 21780890
[TBL] [Abstract][Full Text] [Related]
17. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Sharma P; Johnson DA; Monyak JT; Illueca M
Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
Lee RD; Vakily M; Mulford D; Wu J; Atkinson SN
Aliment Pharmacol Ther; 2009 Apr; 29(8):824-33. PubMed ID: 19243357
[TBL] [Abstract][Full Text] [Related]
19. Dexlansoprazole for the treatment of esophagitis and GERD.
Davies SL
Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
Laine L; Katz PO; Johnson DA; Ibegbu I; Goldstein MJ; Chou C; Rossiter G; Lu Y
Aliment Pharmacol Ther; 2011 Jan; 33(2):203-12. PubMed ID: 21114792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]